Polyrizon (PNY) Forms Strategic Partnership with Clearmind to Advance Intranasal MEAI for CNS Disorders

Polyrizon Pharmaceuticals (PNY) announced a strategic partnership with Clearmind Pharmaceuticals to co-develop and commercialize intranasal monoclonal antibody therapies for central nervous system disorders. The collaboration focuses on advancing CLEARMIND-101, an investigational therapy for Alzheimer's disease, into Phase III trials. The agreement is expected to strengthen PNY's pipeline and provide a clear path to potential commercialization by 2027. Financial terms were not disclosed, but the combined entity plans to leverage shared R&D costs and distribution capabilities.